James A. Davis

4.6k citations

94 papers · 2.1k indexed · 1 hit paper · h-index 23

Impact in

Complementary and alternative medicine top 2%
- Cardiovascular and exercise physiology
Speech and Hearing top 5%
- Neonatal skin health care

Papers in

Hematology 31
- Multiple Myeloma Research and Treatments 26
Oncology 36
- CAR-T cell therapy research 27
- Peptidase Inhibition and Analysis 5

Co-authors: Tom Smith Thomas W. Storer Vincent J. Caiozzo Philip J. Clements Brigid A. Rea Douglas B. Kent Jack H. Wilmore Hamza Hashmi
Journals: Transplantation and Cellular Therapy (11 papers)Blood (10 papers)Journal of Clinical Oncology (5 papers)Medicine & Science in Sports & Exercise (5 papers)European Journal Of Haematology (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

James A. Davis

82 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

General Social Surveys: 1972 - 1994; cumulative codebook 1994 · 580 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1994 General Social Surveys: 1972 - 1994; cumulative codebook

Peers

Countries citing papers authored by James A. Davis

Since Specialization

Citations

This map shows the geographic impact of James A. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Davis more than expected).

Fields of papers citing papers by James A. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Davis. The network helps show where James A. Davis may publish in the future.

Co-authors

The 25 scholars most cited alongside James A. Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James A. Davis Line = papers co-authored together James A. Davis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience Clinical Lymphoma Myeloma & Leukemia ·Wenhan Zhang, P met bijdragen van Crombé, Razan Mansour, 章子熊谷, Nausheen Ahmed, Muhammad Umair Mushtaq, R. de Peñafort Malagarriga, Kimberly M Green, James A. Davis, Barry Skikne, Zahra Mahmoudjafari, Lesley Lawn, Shebli Atrash, Al‐Ola Abdallah	2025	0
2	Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma Transplantation and Cellular Therapy ·James A. Davis, Danai Dima, Nausheen Ahmed, Recep Yusuf Bekci, Joseph P. McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	2024	1
3	P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Hira Shaikh, Ineke Middeldorp Crispijn, Winda Tieneke Nugraheni, 王建泉, James A. Davis, K Biswal, Schrauben, Nausheen Ahmed, Seinosuke Takemura, Ledan Ye, Rere Paulina Bibiana, I. I. Khalil', Kimberly Green, Ulrike Schueler, Muhammad Umair Mushtaq, R. de Peñafort Malagarriga, Al‐Ola Abdallah, Christopher Strouse, Hamza Hashmi, Shebli Atrash	2024	1
4	Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial Blood ·Tong Wang Yang, C. Dunham, K. Pechars'kyi, Manuel F. Azamar, Rere Paulina Bibiana, Hira Shaikh, Christopher Strouse, James A. Davis, Jack D. Hodgson, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al‐Ola Abdallah, Shebli Atrash, Abdullah Khan, Nausheen Ahmed	2024	1
5	Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma European Journal Of Haematology ·Danai Dima, Razan Mansour, James A. Davis, C. Cheslovas, Людмила Салтан, Mitue KONDO, Ара Гагикович Мусаелян, Byron Daynes, Jack D. Hodgson, Nausheen Ahmed, Al‐Ola Abdallah, Hamza Hashmi	2024	2
6	Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb) Blood ·Dassen Wr, 王建泉, James A. Davis, Khalil Hadjoudj, Brian Hess, 榮治〔ヒ〕垣, Michael Edmonds, Nausheen Ahmed, Marc Hoffmann	2024	2
7	“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma SHILAP Revista de lepidopterología ·Ayaka Tsutsumi, James A. Davis, Gul Kirtil, Enrique Aragon-Viruette, Arni Azis Yuliyantiningsih, Kimberly Green, Brian Hess, Hamza Hashmi	2024	1
8	Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study British Journal of Haematology ·Danai Dima, Jack D. Hodgson, James A. Davis, Leyla Shune, Al‐Ola Abdallah, Hong Li, Recep Yusuf Bekci, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Joseph P. McGuirk, Faiz Anwer, Nausheen Ahmed	2024	10
9	Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma Transplantation and Cellular Therapy ·James A. Davis, Danai Dima, Nausheen Ahmed, Recep Yusuf Bekci, Joseph P. McGuirk, Xuefei Jia, Shahzad Raza, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	2023	18
10	Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience Journal of Hematology ·Barbara A. Karbler, Khalil Hadjoudj, James A. Davis, Arni Azis Yuliyantiningsih, Erin R. Weeda, Arash Velayati, 新原亨, Enrique Aragon-Viruette, Yehua Wang, Charalampos G. Arsoniadis, 児玉憲, Thomas J. Chadderdon, Hamza Hashmi	2023	0
11	Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma Blood ·James A. Davis, Danai Dima, Nausheen Ahmed, Recep Yusuf Bekci, Joseph P. McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	2023	2
12	Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy Transplantation and Cellular Therapy ·James A. Davis, Douglas W. Sborov, Khalil Hadjoudj, 辰也祝, Al‐Ola Abdallah, Joseph P. McGuirk, Nausheen Ahmed, Hamza Hashmi	2023	27
13	Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma Journal of Oncology Pharmacy Practice ·Enrique Aragon-Viruette, Arni Azis Yuliyantiningsih, James A. Davis	2023	8
14	Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience Transplantation and Cellular Therapy ·Danai Dima, James A. Davis, Nausheen Ahmed, Xuefei Jia, Miguel Peña, Hira Shaikh, Leyla Shune, Gurbakhash Kaur, Jack Khouri, Aimaz Afrough, Christopher Strouse, Ineke Middeldorp Crispijn, Zahra Mahmoudjafari, Shahzad Raza, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	2023	40
15	Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature Annals of Hematology ·Блудова Ирина Валентиновна, Luis E.T. Rodrigues, Hamid Ehsan, James A. Davis, Doris K. Hansen, Hamza Hashmi	2022	2
16	Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature Bone Marrow Transplantation ·Блудова Ирина Валентиновна, Ahsan Wahab, Luis E.T. Rodrigues, James A. Davis, Hamid Ehsan, Hamza Hashmi	2022	9
17	Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature Clinical Lymphoma Myeloma & Leukemia ·SE Widén, Блудова Ирина Валентиновна, Abdulaziz bin Rasheed, Sahila Chaudhry Sahila Chaudhry, James A. Davis, Hamza Hashmi, Muhammad Husnain	2022	6
18	‘Fast but not so Furious’: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy Clinical Lymphoma Myeloma & Leukemia ·James A. Davis, Guri Jaer, Arni Azis Yuliyantiningsih, Sibel Laçiner-Gürlevik, Hamza Hashmi	2022	1
19	Monochromatic Soft X-Ray Self-Emission Imaging in Dense Z Pinches AIP conference proceedings ·B. Jones, C. Deeney, Chr. Meyer, C. A. Coverdale, P.D. LePell, J. P. Apruzese, R. W. Clark, James A. Davis, Kyle Peterson	2007	2
20	Effect of heterosis on performance of mice across three environments. Journal of Animal Science ·James A. Davis, W. R. Lamberson	1991	5

About James A. Davis

James A. Davis is a scholar working on Hematology, Oncology, Genetics, Pathology and Forensic Medicine and Complementary and alternative medicine, having authored 94 papers that have together received 2.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (27 papers), Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Peptidase Inhibition and Analysis (5 papers), Laser-induced spectroscopy and plasma (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Complementary and alternative medicine (209 citations), Speech and Hearing (124 citations), Orthopedics and Sports Medicine (149 citations), Occupational Therapy (70 citations) and Hematology (161 citations). James A. Davis has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Tom Smith, Thomas W. Storer, Vincent J. Caiozzo, Philip J. Clements, Brigid A. Rea, Douglas B. Kent, Jack H. Wilmore, Hamza Hashmi, William J. Raynor and Gary L. Grove. Their work appears in journals such as Transplantation and Cellular Therapy, Blood, Journal of Clinical Oncology, Medicine & Science in Sports & Exercise and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact